Invivyd, Inc. (IVVD) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Invivyd, Inc. (IVVD) closed at USD 0.61 on 2026-10-14, a change of -71.3 % over the past year, with a market capitalization of USD 197.13M.

Invivyd, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Invivyd, Inc. key figures

Previous close

USD 0.61 (2026-10-14)

1-year change

-71.3 %

Market cap

USD 197.13M

Enterprise value

USD 45.45M

P/E ratio (trailing)

-1.97

P/E ratio (forward)

-1.22

EPS (trailing)

-0.34

EPS (forward)

-0.55

PEG ratio

n/a

Price to book

1.09

Revenue growth

21.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.96

Employees

122

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Invivyd, Inc.

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Invivyd, Inc. and compare it with other stocks.